Literature DB >> 16979840

Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer.

Hitoshi Ishikawa1, Hiroshi Tsuji, Tadashi Kamada, Naoki Hirasawa, Takeshi Yanagi, Jun-Etsu Mizoe, Koichiro Akakura, Hiroyoshi Suzuki, Jun Shimazaki, Hirohiko Tsujii.   

Abstract

PURPOSE: The aim of this study was to determine the risk factors for late gastrointestinal (GI) morbidity after hypofractionated carbon ion radiotherapy (C-ion RT) for prostate cancer. METHODS AND MATERIALS: Between April 2000 and November 2003, a Phase II clinical trial of C-ion RT with a total dose of 66 GyE in 20 fractions was performed on 175 patients with prostate cancer, and the correlations of clinical and dosimetric parameters with the incidence of late GI toxicity in 172 patients who survived for more than 18 months were investigated.
RESULTS: Although no Grade 3-4 late morbidities of the rectum were observed, Grade 1 and 2 morbidities developed in 23 (13%) and 4 (2%) patients, respectively. Dose-volume histogram analysis revealed that the percentage of rectal volume receiving 50% of the prescribed dose (V50) was significantly higher in patients with rectal toxicity than without toxicity (13.2 +/- 5.6% with toxicity; 11.4 +/- 4.0% without toxicity, p = 0.046). Multivariate analysis demonstrated that the use of anticoagulation therapy (p = 0.010) and rectal V50 (p = 0.012) were significant risk factors for the occurrence of Grade 1-2 late GI toxicity.
CONCLUSIONS: Although C-ion RT with hypofractionation yielded favorable results regarding late GI complication, dosimetric parameter was a very important factor in the occurrence of rectal bleeding after C-ion RT as well as photon beam RT. Our results provide useful information for physicians applying charged particle RT in the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16979840     DOI: 10.1016/j.ijrobp.2006.06.056

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  Two-stage treatment with hepatectomy and carbon-ion radiotherapy for multiple hepatic epithelioid hemangioendotheliomas.

Authors:  Shohei Komatsu; Takeshi Iwasaki; Yusuke Demizu; Kazuki Terashima; Osamu Fujii; Atsushi Takebe; Akihiro Toyokawa; Kazuhiro Teramura; Takumi Fukumoto; Yonson Ku; Nobukazu Fuwa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  Surgical spacer placement and proton radiotherapy for unresectable hepatocellular carcinoma.

Authors:  Shohei Komatsu; Yuichi Hori; Takumi Fukumoto; Masao Murakami; Yoshio Hishikawa; Yonson Ku
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

3.  [11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma.

Authors:  Ming-Rong Zhang; Katsushi Kumata; Akiko Hatori; Nobuhiko Takai; Jun Toyohara; Tomoteru Yamasaki; Kazuhiko Yanamoto; Joji Yui; Kazunori Kawamura; Sachiko Koike; Koichi Ando; Kazutoshi Suzuki
Journal:  Mol Imaging Biol       Date:  2009-09-26       Impact factor: 3.488

Review 4.  Individual response of humans to ionising radiation: governing factors and importance for radiological protection.

Authors:  K E Applegate; W Rühm; A Wojcik; M Bourguignon; A Brenner; K Hamasaki; T Imai; M Imaizumi; T Imaoka; S Kakinuma; T Kamada; N Nishimura; N Okonogi; K Ozasa; C E Rübe; A Sadakane; R Sakata; Y Shimada; K Yoshida; S Bouffler
Journal:  Radiat Environ Biophys       Date:  2020-03-07       Impact factor: 1.925

5.  Carbon ion irradiation of the human prostate cancer cell line PC3: a whole genome microarray study.

Authors:  Annelies Suetens; Marjan Moreels; Roel Quintens; Sabina Chiriotti; Kevin Tabury; Arlette Michaux; Vincent Grégoire; Sarah Baatout
Journal:  Int J Oncol       Date:  2014-02-03       Impact factor: 5.650

6.  A retrospective study of late adverse events in proton beam therapy for prostate cancer.

Authors:  Hirokazu Makishima; Hitoshi Ishikawa; Keiichi Tanaka; Yutaro Mori; Masashi Mizumoto; Kayoko Ohnishi; Teruhito Aihara; Nobuyoshi Fukumitsu; Toshiyuki Okumura; Hideyuki Sakurai
Journal:  Mol Clin Oncol       Date:  2017-08-11

7.  Dosimetric impact of using a commercial metal artifact reduction tool in carbon ion therapy in patients with hip prostheses.

Authors:  Jingfang Zhao; Weiwei Wang; Kambiz Shahnaz; Xianwei Wu; Jingfang Mao; Ping Li; Qing Zhang
Journal:  J Appl Clin Med Phys       Date:  2021-06-23       Impact factor: 2.102

8.  Risk factors for rectal bleeding associated with I-125 brachytherapy for prostate cancer.

Authors:  Kosaku Harada; Hitoshi Ishikawa; Yoshitaka Saito; Soken Nakamoto; Hidemasa Kawamura; Masaru Wakatsuki; Toru Etsunaga; Yutaka Takezawa; Mikio Kobayashi; Takashi Nakano
Journal:  J Radiat Res       Date:  2012-08-01       Impact factor: 2.724

9.  Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks.

Authors:  T Nomiya; H Tsuji; K Maruyama; S Toyama; H Suzuki; K Akakura; J Shimazaki; K Nemoto; T Kamada; H Tsujii
Journal:  Br J Cancer       Date:  2014-04-10       Impact factor: 7.640

10.  Surgical spacer placement prior carbon ion radiotherapy (CIRT): an effective feasible strategy to improve the treatment for sacral chordoma.

Authors:  Cobianchi Lorenzo; Peloso Andrea; Vischioni Barbara; Panizza Denis; Fiore Maria Rosaria; Fossati Piero; Vitolo Viviana; Iannalfi Alberto; Ciocca Mario; Silvia Brugnatelli; Dominioni Tommaso; Dario Bugada; Maestri Marcello; Alessiani Mario; Valvo Francesca; Orecchia Roberto; Dionigi Paolo
Journal:  World J Surg Oncol       Date:  2016-08-09       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.